Hydrapres (HPS) fair value: what the stock is really worth
As of Oct 23, 2026: fair value (intrinsic value) of Hydrapres stock PLN 0.49, price PLN 0.48, upside +2.5%, quality 40 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?Yes
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 24, 2026.
How to read this chart
60‑month range 0.2600 PLN – 0.7200 PLN · fair‑value band 0.3100 PLN – 0.8100 PLN · the 0.4780 PLN price screens below the 0.4900 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 24, 2026.
Follow Hydrapres in your weekly email
Every Wednesday you see whether Hydrapres is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hydrapres S.A. engages in the production of pressed steel and aluminum elements worldwide. It is also involved in the designing and manufacturing of metal stamping tools; and production of pressed steel elements using mechanical and hydraulic presses. The company is based in Solec Kujawski, Poland.
Show moreShow less
Hydrapres S.A. operates as a subsidiary of Promack Spolka Z Ograniczona Odpowiedzialnoscia.
Stock analysis
Hydrapres (HPS) currently trades at 0.4780 PLN, while our model-based Fair Value estimate is 0.4900 PLN, so the stock looks roughly fairly valued today (gap 2.4%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 0.5700 PLN per share, and 5 of the 7 models we run sit above the 0.4780 PLN price.
Bear case: the Asset-Based group reads lowest at 0.1800 PLN, and 2 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.3100 PLN (bear) to 0.8100 PLN (bull), the price of 0.4780 PLN sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Industrials sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Hydrapres reported revenue of 29.0M PLN in FY2025 versus 32.6M PLN in FY2021, a compound −2.9%/yr. Reported net income was −6.1M PLN in FY2025.
Key figures
Market cap 25.3M PLN (≈ $6.4M) Micro · P/E ratio 57.4 · EPS (TTM) 0.0071 PLN · Net margin −21.2% · Return on equity 137% · Return on assets (EBIT) −9.0% · Free cash flow 2.0M PLN · Net debt 12.1M PLN.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 19% below its 52-week high and 29% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 4% fair-value upside, at 3%, HPS screens richer than that median.
Fair Value models
Bear0.3100 PLNFair Value 0.4900 PLNBull0.8100 PLN
Price 0.4780 PLN · Upside +2.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0058 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−13.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.1%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.8% (2016) → −15.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Poland: IMF forecast 3.1% a year to 2030, 4.6% from 2016 to 2025) that is about +7.1% a year for the price.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hydrapres Fair Value". https://www.fairvalue-calculator.com/stock/HPS
Frequently asked questions
Is Hydrapres (HPS) overvalued or undervalued?
As of Oct 24, 2026, our model estimates a fair value of 0.4900 PLN versus a price of 0.4780 PLN, about +3% upside (fairly valued).
What is the fair value of HPS?
Our model-based fair value for Hydrapres is 0.4900 PLN (as of Oct 24, 2026), built from audited fundamentals. The current price: 0.4780 PLN.
What is the quality score of HPS?
Hydrapres has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hydrapres (HPS)?
Our model-based price target is the fair value of 0.4900 PLN (as of Oct 24, 2026) from 7 valuation models. Cautious scenario 0.3100 PLN, optimistic scenario 0.8100 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Hydrapres stock forecast for 2026?
Our models put fair value at 0.4900 PLN, about +3% upside versus a price of 0.4780 PLN (fairly valued). Cautious scenario 0.3100 PLN, optimistic scenario 0.8100 PLN. The calculation is refreshed regularly with new filings.
What growth is priced into Hydrapres (HPS)?
For today's price to be fair in a discounted-cash-flow model, Hydrapres would have to grow free cash flow by +10.5 % per year for five years (discount rate 10.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +1.9 % per year. As of Oct 24, 2026.
What discount rate (WACC) does the fair value of HPS use?
Our models discount Hydrapres at 10.6 %: a base by market capitalisation (nano), country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hydrapres that is +10.5 % per year a year over ten years, using the same discount rate (10.6 %) and the same formula as our fair value.
How much growth has Hydrapres (HPS) delivered so far?
Over the past 5 years revenue at Hydrapres grew +1.9 % a year. The price currently implies +10.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hydrapres (HPS) growing?
The median revenue growth in the sector is +7.6 % a year. That is the yardstick for the growth priced into Hydrapres (+10.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hydrapres (HPS)?
The free-cash-flow yield on the price is 7.81 %: that much free cash flow Hydrapres produces per unit of market value. When it exceeds the discount rate of our models (10.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hydrapres (HPS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hydrapres it is 0.4900 PLN per share (as of Oct 24, 2026), against a price of 0.4780 PLN. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Hydrapres stock overvalued or undervalued in 2026?
As of Oct 24, 2026, HPS trades below its calculated fair value: price 0.4780 PLN, fair value 0.4900 PLN, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HPS?
No. The price is what the market pays today (0.4780 PLN); the fair value is what the company's own numbers justify (0.4900 PLN). For Hydrapres the two are 0.0120 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Hydrapres worth?
The market values Hydrapres at about 25.3M PLN (market capitalisation, as of Oct 24, 2026). Per share that is 0.4780 PLN; our models calculate a fair value of 0.4900 PLN per share.
What do the bullish and bearish scenarios say about HPS?
Our models span a range for Hydrapres: cautious scenario 0.3100 PLN, base 0.4900 PLN, optimistic 0.8100 PLN per share (as of Oct 24, 2026, price 0.4780 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HPS?
Hydrapres trades at a price-to-earnings ratio of 57.4 (as of Oct 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.4900 PLN is built from several models across several years. Other multiples: P/B 0.8.
How solid is the balance sheet of Hydrapres (HPS)?
Balance-sheet figures for Hydrapres (as of Oct 24, 2026): return on equity 137.2%, debt of 1.39 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is HPS from its 52-week high?
Hydrapres trades at 0.4780 PLN, about 19% below its 52-week high of 0.5900 PLN and 29% above the low of 0.3700 PLN (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of 0.4900 PLN is for.
Which stocks are comparable to Hydrapres?
From the same area (Industrials) we also value SPG Co, Sungho Electronics Corp, BHI Co, VITZROCELL Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hydrapres stock attractive at the current price?
The data as of Oct 24, 2026: price 0.4780 PLN, calculated fair value 0.4900 PLN (+3%), Quality Score 40/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HPS calculated?
We run Hydrapres through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.4900 PLN, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.3 % above its aggregate fair value. Hydrapres currently trades 2 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hydrapres (HPS)?
The closing price on Oct 23, 2026 was 0.4780 PLN. Our model-based fair value is 0.4900 PLN, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hydrapres right now?
The model range is unusually wide (0.3100 PLN to 0.8100 PLN). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Hydrapres
How large is the market capitalisation of Hydrapres (HPS)?
The market capitalisation of Hydrapres is 25.3M PLN (≈ $6.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Hydrapres (HPS)?
Earnings per share at Hydrapres are 0.0071 PLN (price ÷ EPS = P/E 57.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hydrapres (HPS)?
The net margin of Hydrapres is −21.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hydrapres (HPS)?
The return on equity (ROE) of Hydrapres is 137% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hydrapres (HPS)?
On an EBIT basis the return on assets of Hydrapres is −9.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net debt does Hydrapres (HPS) carry?
The net debt of Hydrapres is 12.1M PLN (fiscal year 2025, ≈ 6.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hydrapres in the live analysis
One click puts Hydrapres on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
